Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Maintains Target Price $12
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $17
Craig-Hallum Maintains Buy on Bioventus, Raises Price Target to $17
Analysts Are Bullish on These Healthcare Stocks: Bioventus (BVS), Sight Sciences (SGHT)
Bioventus Analyst Ratings
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $12
Bioventus Analyst Ratings
Craig-Hallum Maintains Buy on Bioventus, Raises Price Target to $12
Buy Rating Affirmed: Bioventus's Strong Q2 Performance and Strategic Growth Outlook
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating
Canadian Investment Banking Group: Maintaining the Bioventus (BVS.US) rating, adjusted from buy to buy rating, and adjusted the target price from $7.00 to $8.00.
Bioventus Analyst Ratings
Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $8
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Ligand Pharma (LGND) and Bioventus (BVS)
Bioventus Analyst Ratings
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Bioventus (BVS) and Pliant Therapeutics (PLRX)
Analysts Offer Insights on Healthcare Companies: Clene (CLNN), REPRO-MED Systems (KRMD) and Bioventus (BVS)
Analysts Are Bullish on Top Healthcare Stocks: Bioventus (BVS), Palatin Technologies (PTN)
Canaccord Genuity Upgrades Bioventus to Buy, Raises Price Target to $7